This agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression 1%Based onOncotype DX,a score of 35will receivethis treatmentThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis treatmentmodality isalwayscombined withlumpectomysurgeryThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThe onlysteroidalaromataseinhibitor in itsdrug classDuration of timepatients willtakeabemaciclib inearly stagediseaseBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerPreferredfrequencyof GnRHagonistsPreferredregimen forHR+ diseasefor frail/elderlypatientsThis drugclass are thebackbone ofHR+ diseaseThis agentshould beinitiated withneratinib for thefirst 8 weeksPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis agent cancauseendometrialcancer, but hasbone densityprotective effectThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression 1%Based onOncotype DX,a score of 35will receivethis treatmentThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis treatmentmodality isalwayscombined withlumpectomysurgeryThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThe onlysteroidalaromataseinhibitor in itsdrug classDuration of timepatients willtakeabemaciclib inearly stagediseaseBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerPreferredfrequencyof GnRHagonistsPreferredregimen forHR+ diseasefor frail/elderlypatientsThis drugclass are thebackbone ofHR+ diseaseThis agentshould beinitiated withneratinib for thefirst 8 weeksPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis agent cancauseendometrialcancer, but hasbone densityprotective effectThis agent canbe added toLN+ HER2+disease givenwithtrastuzumab

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  2. 1%
  3. Based on Oncotype DX, a score of 35 will receive this treatment
  4. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  5. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  6. This treatment modality is always combined with lumpectomy surgery
  7. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  8. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  9. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  10. The only steroidal aromatase inhibitor in its drug class
  11. Duration of time patients will take abemaciclib in early stage disease
  12. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  13. This subtype of breast cancer has the lowest relative 5-year survival rate
  14. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  15. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  16. Preferred frequency of GnRH agonists
  17. Preferred regimen for HR+ disease for frail/elderly patients
  18. This drug class are the backbone of HR+ disease
  19. This agent should be initiated with neratinib for the first 8 weeks
  20. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  21. This should be monitored routinely every 3-4 months while receiving trastuzumab
  22. Patients with HER2+ disease continue targeted therapy for this duration
  23. This agent can cause endometrial cancer, but has bone density protective effect
  24. This agent can be added to LN+ HER2+ disease given with trastuzumab